EJNMMI Radiopharmacy and Chemistry

SJR Rank #7,518H-index: 36SJR: 0.752Best quartile: Q1Open AccessAPC: US$2,290Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Springer Science and Business Media Deutschland GmbH

Country

Switzerland

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Analytical ChemistryQ1
  • PharmacologyQ2
  • Pharmacology (medical)Q2
  • Radiology, Nuclear Medicine and ImagingQ2

Areas: Chemistry · Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsPeptidase Inhibition and AnalysisProstate Cancer Treatment and ResearchRadioactive Decay and Measurement TechniquesChemical Reactions and IsotopesNeuroendocrine Tumor Research AdvancesMedical Imaging and Pathology StudiesMonoclonal and Polyclonal Antibodies ResearchCancer, Hypoxia, and Metabolism

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs04590135180

Documents per Year

202220250255075100

Detailed Information

ISSN

2365-421X

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

3.30

References per Document

44.39

Coverage

2016-2026

Scope

EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers.

Metrics from SCImago Journal Rank 2025. View on SCImago